Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...

Descrición completa

Detalles Bibliográficos
Main Authors: Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng
Formato: Artigo
Idioma:English
Publicado: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Pharmacology
Subjects:
NSCLC
PD-L1
cost-effectiveness
pembrolizumab
squamous
non-squamous
Acceso en liña:https://www.frontiersin.org/articles/10.3389/fphar.2021.803626/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.803626/full

Títulos similares